Sterling Pharmaceutical Services, LLC made sterile ophthalmic drugs with manufacturing violations and marketed unapproved new drugs.
What happened
FDA inspected the Dupo, Illinois facility from February 7 to 18, 2022 and found significant violations of current good manufacturing practice (CGMP) for sterile ophthalmic drugs. The violations included inadequate investigations of persistent microbiological contamination in critical aseptic areas and a sterility failure, inadequate environmental monitoring, and poor aseptic practices. FDA also reviewed labels collected during the inspection and found the products were unapproved new drugs.
What FDA found
The firm did not thoroughly investigate unexplained batch failures or adverse environmental monitoring trends, including a sterility failure in an ophthalmic lot.
21 CFR 211.192The firm lacked an adequate environmental monitoring system for aseptic processing areas, including insufficient non-viable particulate and personnel monitoring.
21 CFR 211.42(c)(10)(iv)The firm did not establish or follow adequate written procedures to prevent microbiological contamination and validate aseptic and sterilization processes.
21 CFR 211.113(b)The firm marketed ophthalmic drug products as new drugs without FDA-approved applications.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d), 355(a)
What FDA wants
FDA tells the firm to correct the violations promptly and to provide comprehensive independent risk assessments, remediation plans, corrective action plans, and related data in a written response within 15 working days.
Who should pay attention
- brands that use this contract manufacturer for sterile ophthalmic drugs
- distributors and retailers selling homeopathic eye drops or ointments
- patients and caregivers using ophthalmic drugs, especially for young children
This is a summary. Read the original letter on fda.gov.